Abstract:

Hypertension is one of the most common cardiovascular diseases and a key risk factor of many diseases such as coronary atherosclerotic heart disease and stroke. However, resistant hypertension is an intractable problem in the management and treatment of hypertension. In recent years, with the advent of catheter-based renal denervation (RDN), a new chapter has been opened for the treatment of resistant hypertension, but the negative result of SYMPLICTY HTN-3 study has led to doubts and drastic debates on RDN. This paper reviews current status and future directions of catheter-based RDN studies through SYMPLICTY HTN-3.

Key words: catheter-based renal denervation, resistant hypertension, SYMPLICTY HTN-3